| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Nusinersen |
| Brand | Spinraza® |
| Indication | Is indicated for the treatment of 5q spinal muscular atrophy (SMA) |
| Assessment Process | |
| Rapid review commissioned | 11/07/2017 |
| Rapid review completed | 02/08/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 14/08/2017 |
| Pre-submission consultation with Applicant | 12/09/2017 |
| Full submission received from Applicant | 31/10/2017 |
| Preliminary review sent to Applicant | 28/11/2017 |
| NCPE assessment re-commenced | 06/12/2017 |
| Factual accuracy sent to Applicant | 08/12/2017 |
| NCPE assessment re-commenced | 14/12/2017 |
| NCPE assessment completed | 19/12/2017 |
| NCPE assessment outcome | Reimbursement Not Recommended at the Submitted Price. |
The HSE has approved reimbursement following confidential price negotiations July 2019.